The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

Canagliflozin review – safety and efficacy profile in patients with T2DM

(2019) Haroon Jakher et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies

(2018) Tracey G. Simon et al.   HEPATOLOGY

Hepatocellular carcinoma

(2018) Alejandro Forner et al.   LANCET

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

(2018) Kumiko Shiba et al.   Scientific Reports

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2018) Masanori Shimizu et al.   DIABETES OBESITY & METABOLISM

Impact of SGLT2 inhibitor to histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus

(2018) Norio Akuta et al.   HEPATOLOGY RESEARCH

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

(2018) Yuya Seko et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

(2017) Kosuke Kaji et al.   INTERNATIONAL JOURNAL OF CANCER

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice

(2017) Koki Obara et al.   Oncotarget

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

(2016) Chikara Komiya et al.   PLoS One

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Functional expression of sodium-glucose transporters in cancer

(2015) Claudio Scafoglio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

(2013) Damayanthi Devineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

(2013) Masato Fujii et al.   Medical Molecular Morphology

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger?

(2011) Anne P.L. Jensen-Urstad et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis

(2010) Judith Ertle et al.   INTERNATIONAL JOURNAL OF CANCER

Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond

(2008) Vadivel Ganapathy et al.   PHARMACOLOGY & THERAPEUTICS